The global clinical trials matching software market size was exhibited at USD 150.83 million in 2022 and is projected to hit around USD 436.16 million by 2032, growing at a CAGR of 11.2% during the forecast period from 2022 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Biotech companies, clinical research organizations, medical device manufacturers, and pharmaceutical manufacturers regularly conduct drug trials to test the safety and efficiency of trials, new drugs, diagnostics, and therapies. The growing prevalence of chronic disease and the increasing need for drug trials are anticipated to drive the growth of the clinical trials matching software market. Clinical trials matching software are time-consuming and cost-effective. Therefore, trials are progressively being conducted in developing regions, as the availability of patient recruitment and trials matching is an important part of drug trials. Clinical trial matching software is one of the most recent expansions in research.
The COVID-19 pandemic led this market to drive significantly globally. Investors are collaborating directly with drug trial-matched software vendors for the advancement of technology and to find solutions for their research purpose. This technology matches patients with drug trials in a simple process for both patients and donors and can also guide patient recruitment. North America is expected to generate the highest revenue share in the global clinical trial matching software in upcoming years.
| Report Coverage | Details |
| Market Size in 2022 | USD 150.83 Million |
| Market Size by 2032 | USD 436.16 Million |
| Growth Rate from 2023 to 2032 | CAGR of 11.2% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Components, By End-User, By Deployment Mode |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
Drivers: Increasing clinical trial activities is expected to drive the market growth
The increasing clinical trial activities globally is anticipated to drive the clinical trials matching software market during the forecast period. The number of clinical trials has risen significantly over the few decades. This is due to the increased infiltration of advanced healthcare technologies coupled with the growing demand for innovative drugs with greater effectiveness. However, a clinical trial matching system is cost-effective and fast, as clinical trials are used to collect and organize data that can also be shared with multiple healthcare providers and distributed across multiple systems. This technology can assist with location identification and recruitment, as well as monitoring and tracing of patient registrations and databases.
Thus, the increasing number of drug trial activities is propelling the clinical trial-matching software market. For instance, according to the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), for the duration of 1999-2021 the United States (157,620) registered the maximum number of drug trials, followed by China (80,330) and japan (57,750)
Restraint: The high cost of matching software’s hampering the growth of the clinical trial matching software market
The high cost of matching systems is hindering the market growth of the clinical trial matching software market. Initiation, contractual term commitment, per user, per the study, training, support and maintenance, validation/ 21 part 11 compliance, and system integration fees cumulatively rise the overall cost requires for the adoption of the clinical trial matching software solutions. Both on-premises systems and SaaS systems include setup fees.
Additional configuration and customization costs are charged to companies based on specific organizational and research requirements. Different cost structures are observed depending on the number of users and the number of sites considered. There are also some fees or terms to consider for clinical trial matching software, as well as routine system maintenance and upgrades.
Opportunity: The supportive government initiatives and companies collaborations for clinical trials matching the software market creating new opportunities.
The supportive government initiatives and various companies partnerships for the Clinical trial matching software market is likely to drive the entry for new participants in the future, driven by awareness and adoption of a growing number of trial activities and technology process. Rapid advancement in technology further encourages market participants to focus significantly on a new applications and the development of innovative devices. In addition, the increasing number of companies offering updated and customized features is contributing to the growth of the market during the forecast period.
However, software developers and companies will likely to depend on partnerships, mergers, collaborations and acquisitions to hold their market position. For instance, in December 2021, Optima pharma, one of the top European CRO, acquired SSS international. The acquisitions support the company to expand its portfolio of Clinical Research study.
COVID-19 Impact
The COVID-19 outbreak is an exceptional global public health emergency that has impacted most of industries and the long term impacts are expected to hamper industry growth over the upcoming years. COVID-19 has caused destruction on global markets and led to severe blocks in many clinical studies aimed at bringing novel treatments to market. Additionally, labor cutting, supply chain disruptions, and other constraints have intensified the situation. Limitations and boundaries have impacted a number of ongoing clinical research studies in different areas of treatment. To overcome the adverse situation, clinical research organizations have created a new COVID-19 vaccine
The COVID-19 outbreak has positively impacted the clinical trials matching software market. Increasing adoption of technologically advanced solutions for drug trials & development and recruited patient data study are the key factors for the rise in the infiltration of CTMS market. Due to the previous current data collection methods, Clinical trial matching software, which had not been used before, was rapidly adopted in clinical trials during the COVID outbreak.
The COVID-19 pandemic has increased the opportunities for Clinical trials matching software market. The health emergency has additionally initiated an increase in the deployment of software technologies. However, the growing demand for software services from clinical research organizations (CRO) to conduct drug trials in the pharma sector is driving the growth of the market.
Based on the components, the global clinical trials matching software market is segmented into services and software. The software segment is expected to hold a large revenue share in the forecast period for global clinical trial matching software. The growth of this segment is backed by high usage and increased adoption of drug trials. Many biotechs, pharma, and other clinical research organization companies, life science organizations are promoting to conduct of complex drug trials. These trials aim to discover new drugs and medical products. In addition, increase in drug trial activity and the proliferation of multisite drug trials, there is a requirement for effective tools to easily manage research, maintain accurate data, and manage aspects of drug trials.
The use of software tools allows investors to efficiently manage drug trials. For instance, in January 2021, as part of the Cancer Research UK’s (CRUK) UpSMART Accelerator, digital ECMT has created and developed clinical trial matching software to support clinical decision-making, profile matching genetics of tumor patients with optimal drug trials, supporting their precision medicine research.
However, the service segment is anticipated to hold considerable growth during the forecast period, owing to the rise in the number of drug trials and the growth of the healthcare insurance industry.
Based on the End-User, the global clinical trials matching software market is segmented into clinical research organizations, pharmaceutical and biotechnology companies, and medical device firms. The pharmaceutical and biotechnology companies segment accounted more than 41% of revenue share in 2021 and is expected to dominate the market with significant revenue share in forecast period for global clinical trials matching software. The growth of this segment is attributed to the large number of drug trials needed to launch the product. This CRO segment is expected to grow at the fastest CAGR during the forecast period.
Clinical research organizations (CROs) provide drug development services through pharmacovigilance, commercialization, and post-approval services to manufacturing organizations with low research and development funds. An investor contracts with the CRO, a project-by-project basis, for drug trials. Companies that cannot afford to conduct extensive drug trials prefer to outsource these services. As a result, the demand for CRO is growing rapidly.
Based on Deployment mode, the global clinical trials matching software market is segmented into on-premises, web, and cloud-based. The web and cloud-based segment dominated the global clinical trials matching software market and accounted for a significant revenue share in the market, owing to the cloud computing model, which is easier to maintain without maintenance cost. Since in-house server infrastructure is not needed, improvement costs are reduced. Referral time is greatly reduced and is accessible from anywhere. Sharing data is very convenient and allows partnerships on various projects.
The on-premises model needs in-house infrastructure, IT support, software license, and longer integration time. Therefore, this model is more expensive and less popular. On the other hand, organizations with highly confidential data, including governments and financial institutions, need the security and privacy of the on-premises environment.
Clinical Trials Matching Software Market Share, By Region, 2021 (%)
| Regions | Revenue Share in 2021 (%) |
| Asia Pacific | 20% |
| North America | 51% |
| Europe | 14.9% |
| Latin America | 8.1% |
| MEA | 6% |
North America dominated the global clinical trials matching software market and accounted for more than 51% of revenue share in 2021. The growth is credited to the adoption of drug trial matching systems by the pharma and biotechnology companies in the United States. Additionally, the supportive government initiatives toward IT, and the increasing adoption of clinical trial matching software and patient matching software are helping to the market growth in this region.
For instance, according to the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), the United States reported the highest number of clinical trials during 1999-2021. Europe is expected to hold significant market share for the clinical trials matching software market, owing to increasing research and development events in the pharmaceutical and biotechnology sector. Major clinical trial companies are partnering with technology service vendors to integrate advanced technologies into the clinical trial process.
Asia Pacific is about to record the rapid CAGR during the forecast period due to the availability of a large number of patients in the region. A large number of companies are aiming to place their research and development activities in Asia Pacific, thereby supporting to the market growth in this region. This growth can be attributed to a rise in the number of healthcare IT projects, a growing economy and an overall improvement in healthcare infrastructure, especially developing countries, such as India and china.
Latin America & Middle East and Africa (LAMEA) is the lowest clinical trial matching software market due to adequate technology, healthcare infrastructure, few players working in the clinical trial market, and low per capita incomes in underdeveloped regions in Africa.
Segments Covered in the Report
By Components
By End-User
By Deployment Mode
By Geography
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
